Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B001 plus paclitaxel or docetaxel in recurrent or metastatic head and neck squamous cell carcinoma
CTR20212937Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
izalontamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20212937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212937.